IRWD
Ironwood Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$680M
5Y Perf.-57.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IRWD vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
IRWD vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IRWD | DBVT |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $680M | $1712.35T |
| Revenue (TTM) | $362M | $0.00 |
| Net Income (TTM) | $151M | $-168M |
| Gross Margin | 70.4% | — |
| Operating Margin | 55.3% | — |
| Forward P/E | 3.1x | — |
| Total Debt | $598M | $22M |
| Cash & Equiv. | $215M | $194M |
IRWD vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IRWD
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Ironwood Pharmaceut… (IRWD) | 100 | 42.9 | -57.1% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IRWD vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IRWD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
IRWD
Ironwood Pharmaceuticals, Inc.
The Growth Play
IRWD carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -15.7%, EPS growth 400.9%, 3Y rev CAGR -10.3%
- -59.2% 10Y total return vs DBVT's -87.0%
- -15.7% revenue growth vs DBVT's -100.0%
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.26
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IRWD | -15.7% revenue growth vs DBVT's -100.0% |
| Quality / Margins | IRWD | 41.8% margin vs DBVT's 0.3% |
| Stability / Safety | DBVT | Beta 1.26 vs IRWD's 2.50 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IRWD | +426.5% vs DBVT's +110.4% |
| Efficiency (ROA) | IRWD | 38.5% ROA vs DBVT's -89.0% |
IRWD vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
IRWD vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIRWDLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
IRWDIronwood Pharmaceutic…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IRWD1/1
Valuation MetricsMultiples, price ratios, and targets
DBVT1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IRWD4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IRWD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IRWD and DBVT operate at a comparable scale, with $362M and $0 in trailing revenue.
| Metric | IRWDIronwood Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $362M | $0 |
| EBITDAEarnings before interest/tax | $201M | -$112M |
| Net IncomeAfter-tax profit | $151M | -$168M |
| Free Cash FlowCash after capex | $112M | -$151M |
| Gross MarginGross profit ÷ Revenue | +70.4% | — |
| Operating MarginEBIT ÷ Revenue | +55.3% | — |
| Net MarginNet income ÷ Revenue | +41.8% | — |
| FCF MarginFCF ÷ Revenue | +31.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +158.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +2.0% | +91.5% |
IRWD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | IRWDIronwood Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $680M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | 27.80x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 3.14x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 8.81x | — |
| Price / SalesMarket cap ÷ Revenue | 2.30x | — |
| Price / BookPrice ÷ Book value/share | — | 0.66x |
| Price / FCFMarket cap ÷ FCF | 5.35x | — |
DBVT leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
IRWD leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), IRWD scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | IRWDIronwood Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | — | -130.2% |
| ROA (TTM)Return on assets | +38.5% | -89.0% |
| ROICReturn on invested capital | +54.0% | — |
| ROCEReturn on capital employed | +50.9% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $382M | -$172M |
| Cash & Equiv.Liquid assets | $215M | $194M |
| Total DebtShort + long-term debt | $598M | $22M |
| Interest CoverageEBIT ÷ Interest expense | 8.43x | -189.82x |
IRWD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — IRWD and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IRWD five years ago would be worth $3,800 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, IRWD leads with a +426.5% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs IRWD's -26.5% — a key indicator of consistent wealth creation.
| Metric | IRWDIronwood Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -2.3% | +4.9% |
| 1-Year ReturnPast 12 months | +426.5% | +110.4% |
| 3-Year ReturnCumulative with dividends | -60.3% | +19.7% |
| 5-Year ReturnCumulative with dividends | -62.0% | -69.1% |
| 10-Year ReturnCumulative with dividends | -59.2% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -26.5% | +6.2% |
Evenly matched — IRWD and DBVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than IRWD's 2.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs IRWD's 72.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IRWDIronwood Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.50x | 1.26x |
| 52-Week HighHighest price in past year | $5.78 | $26.18 |
| 52-Week LowLowest price in past year | $0.53 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +72.1% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 68.4 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates IRWD as "Hold" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 15.1% for IRWD (target: $5).
| Metric | IRWDIronwood Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $4.80 | $46.33 |
| # AnalystsCovering analysts | 30 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IRWD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 2 (Valuation Metrics, Risk & Volatility). 1 tied.
Best OverallIronwood Pharmaceuticals, I… (IRWD)Leads 2 of 6 categories
Loading custom metrics...
IRWD vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IRWD or DBVT a better buy right now?
Ironwood Pharmaceuticals, Inc.
(IRWD) offers the better valuation at 27. 8x trailing P/E (3. 1x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IRWD or DBVT?
Over the past 5 years, Ironwood Pharmaceuticals, Inc.
(IRWD) delivered a total return of -62. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: IRWD returned -59. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IRWD or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Ironwood Pharmaceuticals, Inc. 's 2. 50β — meaning IRWD is approximately 99% more volatile than DBVT relative to the S&P 500.
04Which has better profit margins — IRWD or DBVT?
Ironwood Pharmaceuticals, Inc.
(IRWD) is the more profitable company, earning 8. 1% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRWD leads at 40. 1% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — IRWD leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is IRWD or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
06Which pays a better dividend — IRWD or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IRWD or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Ironwood Pharmaceuticals, Inc. (IRWD) carries a higher beta of 2. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, IRWD: -59. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IRWD and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.